• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Japan·Consumer Cyclical·4937.T
Share

Waqoo Inc. Stocks

¥ 1518Last Updated 23.07.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

¥ 32.48M

¥ 1518
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 2005 and headquartered in Tokyo, Japan, Waqoo Inc. is primarily engaged in the formulation, production, and sale of cosmetic goods across the Japanese market. Its extensive lineup, sold under the HADA NATURE brand through its dedicated e-commerce platform, encompasses a variety of skincare items such as moisturizing gels, facial and hot cleansers, whitening serums and washes, general serums, protein-based products, and makeup bases. The company also offers hair care solutions, including shampoos, hair oils and masks, and head spa hair growth treatments. Furthermore, Waqoo Inc. diversifies its business by providing medical support services, particularly advertising, and specialized contract services for regenerative medicine, focusing on the processing of blood-derived and fat-derived stem cells.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

25.07.2026 05:03

SpaceX has successfully tested the Starship rocket for the first time since its IPO

25.07.2026 04:30

Paramount has put its merger with Warner Bros. on hold for nearly a year

25.07.2026 02:56

Trump Threatened the European Union with New Tariffs Over Google's Billion-Dollar Fine

25.07.2026 02:12

Anthropic has introduced an affordable AI model for everyday tasks

25.07.2026 01:30

"FOMO Is Turning Into a Fear of Overinvesting": Nasdaq Lost More Than 2% Over the Week

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026